Global Health Alert: WHO Confirms 2,501 New Mpox Cases in October as Clade Ib Variant Establishes Community Transmission in US and Europe

December 10, 2025

GENEVA — The World Health Organization (WHO) has reported 2,501 new confirmed cases of mpox and 12 deaths across 44 countries in October 2025, signaling a persistent global health challenge. In a situation report released Tuesday, the global health body warned that while case numbers have stabilized in some regions, the more severe Clade Ib strain of the monkeypox virus (MPXV) has now established community transmission outside of Africa, including in the United States and several European nations.

The data underscores a shifting epidemiological landscape where local transmission chains are replacing travel-related cases in key non-endemic regions. This development raises concerns among public health experts about the virus’s ability to entrench itself in new populations despite prior containment efforts.

Key Findings: A Persistent Global Threat

According to the latest WHO external situation report, the African Region remains the epicenter of the crisis, accounting for approximately 75% of the global caseload in October. Between October 12 and November 23 alone, 21 African nations reported active transmission, with the Democratic Republic of the Congo (DRC), Liberia, Ghana, Kenya, and Uganda bearing the highest burden. Notably, Mali reported its first-ever confirmed case of mpox during this period, indicating a geographic expansion of the virus within the continent.

However, the most alarming development for global health authorities is the spread of Clade Ib, a strain distinct from the Clade IIb variant that caused the 2022 global outbreak. Clade I viruses have historically been associated with more severe disease and higher mortality rates than Clade II.

Critical Developments:

• Community Transmission Identified: The WHO has now classified Italy, Malaysia, the Netherlands, Portugal, Spain, and the United States as experiencing “community transmission” of Clade Ib. This means cases are occurring in individuals with no recent travel history to endemic regions.

• New Imported Cases: Travelers arriving in Belgium, Germany, Greece, and the United Kingdom have tested positive for Clade Ib.

• Demographics: Of 43 recently confirmed Clade Ib cases outside Africa (recorded Sept 5–Nov 24), nearly half (22) were documented among men who have sex with men (MSM), highlighting a specific risk group that requires targeted engagement.

Expert Perspectives and “Recombinant” Strains

The complexity of the viral evolution was further highlighted this week by reports from the UK Health Security Agency (UKHSA), which identified a “recombinant” mpox virus in England—a strain containing genetic material from both Clade Ib and Clade IIb.

Dr. Boghuma Titanji, an infectious disease expert and Assistant Professor of Medicine at Emory University, emphasized the gravity of this evolution in a statement regarding the findings.

“The key concern now is whether events like this will alter the virus’s transmissibility or virulence,” Dr. Titanji noted. “This is precisely what experts in the field feared would happen if the virus continued to spread globally without a decisive response to stop it.”

While the WHO assesses the risk to the general population as “low,” the risk for men who have sex with men with new or multiple partners is currently classified as “moderate.”

Dr. Katy Sinka, head of sexually transmitted infections at UKHSA, urged calm but vigilance. “It’s normal for viruses to evolve, and further analysis will help us understand more about how mpox is changing,” she stated, reinforcing that vaccination remains a “proven effective way to protect yourself against severe disease.”

Context: Clade Ib vs. Clade II

To understand the significance of these reports, it is essential to distinguish between the viral strains:

• Clade II (formerly West African clade): drove the 2022 global outbreak. It generally causes milder illness and has a lower fatality rate (historically <1%).

• Clade I (formerly Congo Basin clade): historically causes more severe illness with fatality rates up to 10% in some outbreaks, though recent Clade Ib cases outside Africa have not yet shown such high mortality, potentially due to better access to healthcare.

The current 0.5% Case Fatality Ratio (CFR) reported in October (12 deaths among 2,501 cases) reflects a mix of these clades, but the persistent deaths—primarily in the African region—highlight the disparity in healthcare access.

Implications for Public Health

The confirmation of community transmission in Western nations suggests that border controls and travel screening alone are no longer sufficient to contain Clade Ib. Public health strategies must now pivot back to:

1. Enhanced Surveillance: Rapid testing and genomic sequencing to distinguish between clades.

2. Targeted Vaccination: Ensuring at-risk populations (particularly the MSM community and healthcare workers) are up to date with mpox vaccinations.

3. Stigma Reduction: Communication strategies that alert at-risk groups without stigmatizing them, a lesson learned painfully during the 2022 outbreak.

“When mpox outbreaks are not rapidly contained, and human-to-human transmission is not interrupted, there is a risk of sustained community transmission,” the WHO report warned, urging countries to maintain robust surveillance systems.

What This Means for You

For the average person, the risk remains low. However, awareness is the first line of defense.

• Symptoms to Watch: unexplained rash, fever, swollen lymph nodes, and muscle aches.

• Transmission: The virus spreads primarily through close skin-to-skin contact, including sexual contact.

• Action: If you develop symptoms or believe you have been exposed, isolate immediately and contact a healthcare provider. Vaccination is recommended for those in high-risk groups.

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.

References

1. World Health Organization (WHO). (2025, December). Mpox: Multi-country External Situation Report no. 60. World Health Organization.

2. Nagaland Tribune. (2025, December 9). 2,501 new confirmed mpox cases, 12 deaths reported from 44 countries in October: WHO. Retrieved from nagalandtribune.in